Literature DB >> 18478216

Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells.

Yan-Gang Zhou1, Kun-Yan Li, Huan-De Li.   

Abstract

OBJECTIVE: Perospirone (PER) is a novel atypical antipsychotic drug for the treatment of schizophrenia and other psychotic disorders. The multidrug resistance transporter, P-glycoprotein (Pgp), is involved in the efflux transport of several antipsychotics across the blood-brain barrier (BBB). The aim of the present study was to evaluate the modulating effect of PER on both Pgp activity and expression in Caco-2 cell monolayers.
METHODS: The effects of PER were analyzed by means of rhodamine 123 (Rhd 123) assays, and those of Pgp expression were analyzed by flow cytometry and reverse transcriptase-PCR.
RESULTS: Perospirone at concentrations of 0.01-30 microM, which were found to be non-cytotoxic towards the Caco-2 cells, was observed to inhibit Pgp-mediated efflux transport of Rhd 123 in the cells as well as to down-regulate the cellular Pgp protein and MDR1 mRNA levels in a concentration-dependent manner. In the rhodamine accumulation assays, 30 microM PER produced a 429% increase of the cellular Rhd 123 concentration, which exceeded the inhibitory effect of the well-known Pgp inhibitor verapamil.
CONCLUSION: Our findings provide experimental evidence that PER is an inhibitor of Pgp which interferes directly and indirectly with the function of Pgp.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18478216     DOI: 10.1007/s00228-008-0487-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  40 in total

1.  Perospirone is a new generation antipsychotic: evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain.

Authors:  Yoshimoto Sekine; Yasuomi Ouchi; Nori Takei; Etsuji Yoshikawa; Hiroyuki Okada; Yoshio Minabe; Kazuhiko Nakamura; Katsuaki Suzuki; Yasuhide Iwata; Kenji J Tsuchiya; Genichi Sugihara; Norio Mori
Journal:  J Clin Psychopharmacol       Date:  2006-10       Impact factor: 3.153

Review 2.  ABC drug transporter at the blood-brain barrier: effects on drug metabolism and drug response.

Authors:  Martin Ebinger; Manfred Uhr
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

3.  Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Authors:  Kelly M Mahar Doan; Joan E Humphreys; Lindsey O Webster; Stephen A Wring; Larry J Shampine; Cosette J Serabjit-Singh; Kimberly K Adkison; Joseph W Polli
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

4.  Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.

Authors:  Kazuyoshi Mutoh; Satomi Tsukahara; Junko Mitsuhashi; Kazuhiro Katayama; Yoshikazu Sugimoto
Journal:  Cancer Sci       Date:  2006-08-22       Impact factor: 6.716

5.  Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex.

Authors:  Tatsuki Yoshino; Koichi Nisijima; Katsutoshi Shioda; Kunio Yui; Satoshi Katoh
Journal:  Neurosci Lett       Date:  2004-06-24       Impact factor: 3.046

6.  Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists.

Authors:  C E Herzog; M Tsokos; S E Bates; A T Fojo
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

Review 7.  Schizophrenia.

Authors:  Kim T Mueser; Susan R McGurk
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

8.  Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.

Authors:  Amal Abou El Ela; Sebastian Härtter; Ulrich Schmitt; Christoph Hiemke; Hildegard Spahn-Langguth; Peter Langguth
Journal:  J Pharm Pharmacol       Date:  2004-08       Impact factor: 3.765

Review 9.  Perospirone (Sumitomo Pharmaceuticals).

Authors:  Tomas de Paulis
Journal:  Curr Opin Investig Drugs       Date:  2002-01

Review 10.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more
  1 in total

1.  New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro.

Authors:  Iris Chiara Salaroglio; Elena Gazzano; Joanna Kopecka; Konstantin Chegaev; Costanzo Costamagna; Roberta Fruttero; Stefano Guglielmo; Chiara Riganti
Journal:  Molecules       Date:  2018-06-09       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.